Moleculin reverse split plans announced on October 16, 2026, call for every 20 common shares to become one, effective October 20. The biotechnology company’s shares fell more than 16% in pre-market trading on the announcement day, although the price move alone does not establish its cause.
Key Takeaways
- Split-adjusted trading is scheduled to begin October 20 under the existing MBRX ticker.
- Outstanding common shares will fall from approximately 20.91 million to 1.05 million.
- Fractional shares will be paid in cash rather than issued.
Table of Contents
- Moleculin reverse split follows shareholder authorization
- What changes for shareholders and equity awards
- Pre-market decline is separate from the split adjustment
- Conclusion
Moleculin reverse split follows shareholder authorization
Moleculin’s reverse stock split filing states that the consolidation will take effect at 12:01 a.m. Eastern Time on October 20, 2026. Trading on the Nasdaq Capital Market is scheduled to begin on a post-split basis that day.
Shareholders authorized a reverse split at the annual meeting completed on October 9, allowing the board to select a ratio between 1-for-2 and 1-for-20. The board chose the upper end of that range, and the company filed the required amendment in Delaware.
The consolidation changes the number of shares representing an investment, not the company’s underlying business. It does not itself raise cash or improve operating results.
| Item | Details |
|---|---|
| Trading symbol | MBRX, unchanged |
| New CUSIP | 60855D507 |
| Par value | $0.001 per share, unchanged |
| Authorized common shares | 500 million, unchanged |
What changes for shareholders and equity awards
Every 20 issued and outstanding common shares will automatically combine into one. Holders whose positions do not convert into whole shares will receive cash, without interest, for the fractional portion under the filing’s specified calculation.
Outstanding stock options, restricted stock units and warrants will receive proportionate adjustments to their share counts and, where applicable, exercise prices. Shares reserved under the company’s equity compensation plan will also be reduced proportionately.
Authorized common shares will remain unchanged even as outstanding shares decline. Authorized shares are the ceiling permitted by the company’s charter, rather than shares already issued to investors.
Pre-market decline is separate from the split adjustment
The decline of more than 16% was a pre-market observation on October 16, not a confirmed closing return or the mechanical price adjustment associated with the reverse split.
Moleculin is a clinical-stage pharmaceutical company developing treatments for hard-to-treat cancers and viral diseases. The share consolidation does not change the development status of those programs, and the corporate-action announcement should not be read as a clinical update.
Conclusion
The next scheduled milestone is the October 20 start of split-adjusted trading. The consolidation will reduce outstanding shares while leaving the ticker, par value and authorized share count unchanged.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
